Condition: Colorectal Neoplasms · Gastrointestinal Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Colorado Denver Anschultz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| Start Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
| Severance Hospital Yonsei University Health System | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Hosp Univ Vall D Hebron | Barcelona, Spain | Recruiting |
| Hosp Univ Fund Jimenez Diaz | Madrid, Spain | Recruiting |
| Hosp. Univ. 12 de Octubre | Madrid, Spain | Recruiting |
| Hosp Univ Hm Sanchinarro | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663319